Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47:1200–5.

Article  PubMed  Google Scholar 

Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017;30:797–809.

Article  PubMed  Google Scholar 

Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15:231–47.

Article  PubMed  Google Scholar 

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, et al. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer. 2019;132:59–64.

Article  PubMed  Google Scholar 

Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17:362–87.

Article  PubMed  Google Scholar 

Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017;30:1422–32.

Article  PubMed  Google Scholar 

Crombé A, Alberti N, Villard N, Pilleul F, Buy X, Le Loarer F, et al. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol. 2019;29:4730–41.

Article  PubMed  Google Scholar 

Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, et al. SMARCA4-deficient thoracic sarcomas. Am J Surg Pathol. 2019;43:455–65.

Article  PubMed  Google Scholar 

Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol. 2021;38:83–9.

Article  PubMed  Google Scholar 

Mittal P, Roberts CWM. The SWI/SNF complex in cancer — biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17:435–48.

Article  PubMed  PubMed Central  Google Scholar 

Mashtalir N, D’Avino AR, Michel BC, Luo J, Pan J, Otto JE, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018;175:1272–88.

Article  PubMed  PubMed Central  Google Scholar 

Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun. 2017;8:14648.

Article  PubMed  PubMed Central  Google Scholar 

Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SM, et al. Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet. 2017;49:213–22.

Article  PubMed  Google Scholar 

Ho L, Miller EL, Ronan JL, Ho WQ, Jothi R, Crabtree GR. esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. Nat Cell Biol. 2011;13:903–13.

Article  PubMed  PubMed Central  Google Scholar 

Romero OA, Setien F, John S, Gimenez Xavier P, Gómez López G, Pisano D, et al. The tumour suppressor and chromatin‐remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med. 2012;4:603–16.

Article  PubMed  PubMed Central  Google Scholar 

Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, et al. BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci. 2000;97:7748–53.

Article  PubMed  PubMed Central  Google Scholar 

Moison C, Chagraoui J, Caron M, Gagné J, Coulombe Y, Poirier GG, et al. Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair. Proc Natl Acad Sci. 2021;118:e2019408118.

Article  PubMed  PubMed Central  Google Scholar 

Vélez-Cruz R, Manickavinayaham S, Biswas AK, Clary RW, Premkumar T, Cole F, et al. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Gene Dev. 2016;30:2500–12.

Article  PubMed  PubMed Central  Google Scholar 

Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougoüin A, Moreira M, et al. Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist. 2022;27:501–11.

Article  PubMed  PubMed Central  Google Scholar 

Kawachi H, Kunimasa K, Kukita Y, Nakamura H, Honma K, Kawamura T, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy. 2021;13:799–806.

Article  PubMed  Google Scholar 

Kuwamoto S, Matsushita M, Takeda K, Tanaka N, Endo Y, Yamasaki A, et al. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources. Hum Pathol. 2017;70:92–7.

Article  PubMed  Google Scholar 

Stewart BD, Kaye F, Machuca T, Mehta HJ, Mohammed T, Newsom KJ, et al. SMARCA4-deficient thoracic sarcoma: a case report and review of literature. Int J Surg Pathol. 2020;28:102–8.

Article  PubMed  Google Scholar 

Orvis T, Hepperla A, Walter V, Song S, Simon J, Parker J, et al. BRG1/SMARCA4 inactivation promotes non–small cell lung cancer aggressiveness by altering chromatin organization. Cancer Res. 2014;74:6486–98.

Article  PubMed  PubMed Central  Google Scholar 

Sesboue C, Le Loarer F. SWI/SNF-deficient thoraco-pulmonary neoplasms. Semin Diagn Pathol. 2021;38:183–94.

Article  PubMed  Google Scholar 

Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, et al. Small-cell carcinoma of the ovary, hypercalcemic type–genetics, new treatment targets, and current management guidelines. Clin Cancer Res. 2020;26:3908–17.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Shi H, Zhang W, Bai C, He M, Ta N, et al. Immunotherapy and targeting the tumor microenvironment: current place and new insights in primary pulmonary NUT Carcinoma. Front Oncol. 2021;11:690115.

Article  PubMed  PubMed Central  Google Scholar 

Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, et al. SMARCA4 /BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non–small cell lung cancer. Clin Cancer Res. 2016;22:2396–404.

Article  PubMed  Google Scholar 

Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun. 2019;10:557.

Article  PubMed  PubMed Central  Google Scholar 

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740–53.

Article  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.

Article  PubMed  Google Scholar 

Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 2018;24:1047–57.

Article  PubMed  Google Scholar 

Yap TA, Ahnert JR, Piha-Paul SA, Fu S, Janku F, Karp DD, et al. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol. 2019;37:3014.

Article  Google Scholar 

El OB, Behera M, Kim S, Berry LD, Sica G, Pillai RN, et al. Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience. J Thorac Oncol. 2019;14:876–89.

Article  Google Scholar 

Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, et al. Prognostic impact of KRAS G12C mutation in patients with NSCLC: Results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2021;16:990–1002.

Article  PubMed  Google Scholar 

Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32:1101–10.

Article  PubMed  Google Scholar 

Akhave NS, Biter AB, Hong DS. Mechanisms of resistance to KRAS(G12C)-targeted therapy. Cancer Discov. 2021;11:1345–52.

Article  PubMed  PubMed Central  Google Scholar 

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl J Med. 2021;384:2371–81.

Article  PubMed  PubMed Central  Google Scholar 

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401:733–46.

Article  PubMed  Google Scholar